
浏览全部资源
扫码关注微信
1.北京中医药大学东直门医院脾胃病科,北京 100029
2.北京大学第一医院中医、中西医结合科,北京 100034
沈姝玥,女,24岁,硕士研究生。研究方向:中西医结合治疗消化疾病。
张学智,E-mail:zhang.xuezhi@263.net
收稿日期:2024-09-09,
纸质出版日期:2025-08-25
移动端阅览
沈姝玥,叶晖,王自成,等.荆花胃康胶丸补救治疗幽门螺杆菌感染的多中心随访研究[J].北京中医药,2025,44(8):981-985.
SHEN Shuyue,YE Hui,WANG Zicheng,et al.Multicenter follow-up study on the salvage treatment of Helicobacter pylori infection with Jinghua Weikang Capsules[J]. Beijing Journal of Traditional Chinese Medicine,2025,44(08):981-985.
沈姝玥,叶晖,王自成,等.荆花胃康胶丸补救治疗幽门螺杆菌感染的多中心随访研究[J].北京中医药,2025,44(8):981-985. DOI: 10.16025/j.1674-1307.2025.08.007.
SHEN Shuyue,YE Hui,WANG Zicheng,et al.Multicenter follow-up study on the salvage treatment of Helicobacter pylori infection with Jinghua Weikang Capsules[J]. Beijing Journal of Traditional Chinese Medicine,2025,44(08):981-985. DOI: 10.16025/j.1674-1307.2025.08.007.
目的
2
观察荆花胃康胶丸补救治疗幽门螺杆菌(Hp)感染的效果。
方法
2
选择2019年1月—2023年12月6家医院中经过补救治疗的Hp感染患者488例,采用区组随机方法分为铋剂四联对照组、荆花胃康A组、荆花胃康B组、荆花胃康C组。铋剂四联对照组给予三联疗法[雷贝拉唑(20 mg/次,2次/d)+阿莫西林(AC,1 000 mg/次,2次/d)+呋喃唑酮(FR,100 mg/次,2次/d)]+枸橼酸铋钾(220 mg/次,2次/d)口服,疗程14 d。荆花胃康A组、B组、C组给予三联疗法(同上),疗程14 d;联合荆花胃康胶丸(240 mg/次,2次/d)口服,疗程分别为14、28、10 d。对比4组治疗前及停药后3、6个月症状积分;末次治疗结束1年后复查13C-尿素呼气试验,计算复发率;对比4组疗效。
结果
2
停药3、6个月,4组症状总积分均较治疗前降低(
P
<
0.05),荆花胃康A组、B组大便稀溏、腹胀、嗳气积分均较治疗前及铋剂四联对照组降低(
P
<
0.05);停药6个月,荆花胃康A组、B组、C组症状总积分均低于铋剂四联对照组(
P
<
0.05)。4组复发率比较差异无统计学意义(
P
>
0.05)。荆花胃康A组、B组、C组总有效率均高于铋剂四联对照组(
P
<
0.05)。
结论
2
不同疗程的荆花胃康胶丸联合呋喃唑酮三联疗法,其复发率略低于铋剂四联疗法,患者远期症状改善较铋剂四联疗法更明显。
Objective
2
To observe the effect of
Jinghua Weikang
Capsules
in salvage therapy for
Helicobacter pylori
(Hp) infection.
Methods
2
A total of 488 Hp infected patients who underwent salvage therapy between January 2019 and December 2023 at six hospitals were selected. The patients were randomly divided into four groups using block randomization: the bismuth quadruple therapy control group,
Jinghua Weikang
Group A,
Jinghua Weikang
Group B, and
Jinghua Weikang
Group C. The control group received triple therapy [rabeprazole (20 mg per dose, twice daily) + amoxicillin (1 000 mg per dose, twice daily) + furazolidone (100 mg per dose, twice daily)] combined with bismuth potassium citrate (220 mg per dose, twice daily) for 14 days. Groups A, B, and C received the same triple therapy (14 days) combined with
Jinghua Weikang
Capsules
(240 mg per dose, twice daily) for 14, 28, and 10 days, respectively. Symptom scores were compared before treatment and at 3 and 6 months after discontinuation. The 13C-urea breath test was repeated 1 year after the final treatment to calculate recurrence rates. Efficacy across groups was analyzed.
Results
2
At 3 and 6 months after treatment, the total symptom scores in all groups were lower compared to baseline (
P
<
0.05). Groups A and B showed reduced scores for loose stools, abdominal distension, and belching compared to baseline and the bismuth quadruple therapy control group (
P
<
0.05). At 6 months, total symptom scores in Groups A, B, and C were lower than in the control group (
P
<
0.05). No significant difference in recurrence rates was observed among groups (
P
<
0.05). The overall effective rates in Groups A, B, and C were higher than in the control group (
P
<
0.05).
Conclusion
2
Jinghua Weikang
Capsules
combined with furazolidone-based triple therapy (with varying durations and regimens) demonstrated slightly lower recurrence rates and more sustained symptom improvement compared to bismuth quadruple therapy.
BRAY F , FERLAY J , SOERJOMATARAM I , et al . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin , 2018 , 68 ( 6 ): 394 - 424 .
HUANG YQ , HUANG GR , WU MH , et al . Inhibitory effects of emodin, baicalin, schizandrin and berberine on hefA gene: treatment of Helicobacter pylori-induced multidrug resistance [J ] . World J Gastroenterol , 2015 , 21 ( 14 ): 4225 - 4231 .
张恩恩 , 叶晖 , 刘宇 , 等 . 幽门螺杆菌生物膜效应的研究进展及中医药干预展望 [J ] . 中华中医药学刊 , 2021 , 39 ( 10 ): 97 - 100 .
JIA X , HUANG Q , LIN M , et al . Revealing the novel effect of Jinghua Weikang capsule against the antibiotic resistance of Helicobacter pylori [J ] . Front Microbiol , 2022 ( 13 ): 962354 .
成虹 , 胡伏莲 , 盛剑秋 , 等 . 荆花胃康胶丸联合含呋喃唑酮三联或四联疗法补救治疗幽门螺杆菌感染的多中心随机对照研究 [J ] . 中华医学杂志 , 2016 , 96 ( 40 ): 3206 - 3212 .
黄星涛 , 张学智 , 李宁 , 等 . 荆花胃康胶丸对幽门螺杆菌耐药菌株体外抑菌作用的研究 [J ] . 中国中西医结合消化杂志 , 2010 , 18 ( 5 ): 290 - 293 .
肖惠霞 . 荆花胃康胶丸联合三联疗法补救治疗H .pylori感染多中心随机对照临床研究[D ] . 北京 : 北京中医药大学 , 2022 .
LIU WZ , XIE Y , LU H , et al . Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection [J ] . Helicobacter , 2018 , 23 ( 2 ): e12475 .
中华中医药学会脾胃病分会 . 痞满中医诊疗专家共识(2023) [J ] . 中国中西医结合消化杂志 , 2024 , 32 ( 5 ): 363 - 369 .
郑筱萸 . 中医新药临床研究指导原则(试行) [M ] . 中国医药科技出版社 , 2002 : 361 - 362 .
DE LUCA L , ZAGARI RM , POZZATO P , et al . Measuring dyspepsia: a new severity index validated in Bologna [J ] . Dig Liver Dis , 2004 , 36 ( 12 ): 806 - 810 .
叶晖 , 黄秋月 , 贾晓芬 , 等 . 幽门螺杆菌感染的中西医结合诊疗方案 [J ] . 北京中医药 , 2024 , 43 ( 3 ): 232 - 235 .
刘扬 , 江锋 , 薛婧 , 等 . 基于湿热虫邪探讨幽门螺杆菌感染的中医证治 [J ] . 北京中医药 , 2024 , 43 ( 6 ): 684 - 688 .
叶晖 . 荆花胃康胶丸治疗H .pylori相关性胃炎疗效评价及对H.pylori体内根除作用的实验研究[D ] . 北京 : 北京中医药大学 , 2015 .
叶晖 , 李宁 , 于靖 , 等 . 荆花胃康胶丸对幽门螺杆菌感染小鼠胃黏膜核因子κB p65表达的影响 [J ] . 中国中医药信息杂志 , 2015 , 22 ( 2 ): 60 - 63 .
于靖 , 张学智 , 史宗明 , 等 . 土荆芥挥发油对幽门螺杆菌甲硝唑耐药株及敏感株的体外抗菌作用研究 [J ] . 北京中医药 , 2018 , 37 ( 10 ): 929 - 931 .
史宗明 , 于靖 , 黄秋月 , 等 . 土荆芥对幽门螺杆菌感染小鼠肠道菌群多样性的影响 [J ] . 北京中医药 , 2018 , 37 ( 10 ): 932 - 937 .
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备 11010102006710号